RTW and Rivals Cash In as Biopharma Roars Back

FDA leadership changes, consolidation, and new product launches have fueled a biotech rally, turning life sciences hedge funds into standout performers.

Stephen Taub November 13, 2025

What a difference several months have made for biopharma stocks and the hedge funds that specialize in the sector.Life sciences and biopharma funds had another strong month in October. Since early April, the Nasdaq Biotechnology Index is up nearly 50 percent. Suddenly, a number of

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Contact Info

New York
1270 Avenue of the Americas, Suite 1100
New York, NY 10020
P: +1 212 224 3300

London
4 Bouverie Street
London EC4Y 8AX
P: +44 207 779 8888

Hong Kong
Unit 2488, 24/F
Lee Garden One,
33 Hysan Avenue
Causeway Bay, Hong Kong
P: +852 2912 8001

Corporate

About Us

Leadership Team

Careers

II Press Room

Digital

Masthead

Thought Leadership

Display Advertising

Reprints

FAQs

Events

Events Calendar

Memberships

Subscription

Subscribe to Premium

Register

Register for Free Account

Newsletters

Sign up for II newsletters

© 2025 Institutional Investor LLC. All material subject to strictly enforced copyright laws. Please read our Terms & Conditions, Modern Slavery Act Transparency Statement, Accessibility Statement and Privacy Policy before using the site.

4.12.03 build:2025-12-12 Login